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Abstract : Neuroendocrine ductal carcinoma in situ of the breast（NE-DCIS）was 
recently recognized as a special subtype of DCIS, although the diagnostic criteria 
for NE-DCIS are yet to be established.  DCIS is defined as the immunohisto-
chemical expression of neuroendocrine markers chromogranin A and / or synap-
tophysin in over 50％ of tumor cells.  Here, we investigated whether there are 
signicant differences in magnetic resonance imaging（MRI）ndings between NE-
DCIS and non-NE-DCIS.  The study sample comprised 8 lesions in 7 patients with 
breast NE-DCIS and 71 lesions in 69 patients with non-NE-DCIS who underwent 
preoperative MRI and histopathological diagnosis at our hospital from June 2010 to 
June 2012.  The patients were females aged 34–85 years.  We examined the lesion 
type, pattern of time-signal intensity curve（TIC）on dynamic contrast-enhanced 
MRI（DCE-MRI）, presence or absence of bloody duct ectasia delineation, and 
presence or absence of calcication on mammography（MMG）.  Mass-type lesions 
were significantly more common in breast NE-DCIS than in non-NE-DCIS on 
MRI.  On DCE-MRI, the TIC washout pattern was more commonly observed in 
NE-DCIS than in non-NE-DCIS, and although there was no signicant difference 
in the rate of bloody duct ectasia delineation, it was relatively more common in 
NE-DCIS.  MMG revealed a signicant difference in calcication between non-NE-
DCIS（60.1％）and NE-DCIS（0％）.  Mass-type lesions and TIC washout pattern 
are signicantly more common in patients with NE-DCIS than in those with non-
NE-DCIS on MRI and DCE-MRI.
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Introduction
　Neuroendocrine ductal carcinoma in situ（NE-DCIS）of the breast was recently recognized as 
a special subtype of DCIS.  Kawasaki et al 1） dened DCIS as the immunohistochemical expres-
sion of neuroendocrine markers chromogranin A and / or synaptophysin in over 50％ of tumor 
cells（Figure 1）.  While there are no established diagnostic criteria as of yet for NE-DCIS, it 
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accounts for 6.8％ of DCIS cases and is clinically characterized by abundant bloody nipple dis-
charge 2-4）.
　Several clinicopathological reports of NE-DCIS have described polygonal or fusiform tumor 
cells exhibiting solid, intraductal proliferation, occasionally accompanied by a vascular network 
showing hyalinization.  The tumor cells possess ne granular cytoplasm and are often eosino-
philic, with nuclei characterized by poor atypia and ne granular chromatin（Figure 2）5）.
　To our knowledge, very few studies have reported on the magnetic resonance imaging（MRI）
ndings of NE-DCIS.  We therefore investigated whether patients pathologically diagnosed with 
breast NE-DCIS could be distinguished from those with non-NE-DCIS on preoperative MRI.
Subjects and methods
　This study design was clinical research using opt-out and was approved by the ethics review 
board for clinical research of Showa University Hospital.  Of 100 patients in whom 103 lesions 
Fig. 1.  Immunohistochemical findings of Neuroendocrine ductal carcinoma in situ （NE-DCIS）
a） Chromogranin A,  b） Synaptophysin.
Fig. 2.  Histological findings of Neuroendocrine ductal carcinoma in situ （NE-DCIS） 
a）  hematoxylin-eosin staining （H&E）× 4, original magnification. Tumor cells are apparent growing 
solidly in the duct and a well-developed vascular network is evident. 
b）  H&E × 40, original magnification. Cancer cells with ovoid nuclei showing fine-granular, 
eosinophilic cytoplasm.
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were pathologically diagnosed as DCIS using preoperative MRI in the period from June 2010 to 
June 2012, 21 patients who underwent biopsy using stereotactic vacuum-assisted breast biopsy（ST-
VAB）prior to MRI and 3 in whom the lesion could not be identied using MRI were excluded. 
The study analysis therefore comprised 79 lesions from 76 patients.
　We used the 1.5 Timager Signa System（General Electric, Yokogawa Medical Systems, Japan）
for MRI, with patients in the prone position and imaging performed according to the conditions 
described in Table 1A for the period of 2008–2011 and Table 1B for 2012.  Gadolinium-DTPA
（Magnevist ; Schering, Berlin, Germany）was used as the contrast agent, with 10ml intravenously 
injected, followed by a 10ml ush with physiological saline.
　MRI was used to determine the lesion type（mass, non-mass, or focus）, time–signal intensity 
curve（TIC）pattern（washout, plateau, or persistent）on dynamic contrast-enhanced MRI
（DCE-MRI, as explained later）, and existence of bloody duct ectasia delineation using high-
signal intensity on precontrast T1-weighted imaging.  The existence and extent of calcication was 
determined on mammography（MMG）.
　MRI was used to determine the lesion characteristics such as morphology, but also on the 
extent and pattern of vascularity with the use of contrast medium.  The TIC on DCE-MRI is 
obtained by repeated MRI scans after contrast injection and is a useful tool for breast cancer 
diagnosis.  In this technique, the shape of the time signal strength curve is usually classied into 
three types : persistent strengthening, plateau, or washout.  A persistent curve showing a sustained 
increase in signal intensity after contrast injection correlates with a benign lesion, while a plateau 
curve showing a slow or rapid increase in the beginning followed by a sharp bend and plateau is 
indicative of malignancy.  A washout curve showing a rapid initial rise followed by a drop-off in 
signal intensity with time is considered relatively specic for malignant lesions 6）.  Fisher’s exact test
（a level of signicance of 5％）was used to determine the signicance of intergroup differences.
Results
　The sample included 79 lesions from female patients aged 34–85 years（mean age, 53.7 years）. 
Of these, 8 lesions in 7 patients were consistent with NE-DCIS（age, 39–69 years ; mean age, 57.3 
years）, whereas 71 lesions in 69 patients were non-NE-DCIS（age, 34–85 years ; mean age, 53.3 
years ; Table 2）.  Based on MRI, the lesion type for NE-DCIS was mass in 5（62.5％）patients, 
non-mass in 2（25％）, and focus in 1（12.5％）, whereas for non-NE-DCIS, the lesion type was 
mass in 12（16％）patients, non-mass in 54（76.1％）, and focus in 5（7.0％）.  This indicated that 
mass-type lesions were signicantly more common in NE-DCIS cases and non-mass-type lesions 
were signicantly more common in non-NE-DCIS（P ＝ 0.007）.  On DCE-MRI for NE-DCIS 
patients, TIC showed a washout pattern in 7（87.5％）patients and a plateau in 1（12.5％）, and 
none exhibited the persistent pattern, while for non-NE-DCIS, TIC showed a washout pattern 
in 27（38.0％）patients, a plateau in 20（28.2％）, and a persistent pattern in 24（22.8％）.  The 
washout pattern was thus signicantly more common in NE-DCIS patients.（P ＝ 0.023）.  A 
case of NE-DCIS is presented in Figure 3a–c, depicting the most common mass-type lesion with 
TIC washout pattern on DCE-MRI.  Figure 3d–f shows a case of non-mass-type lesion showing 
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Table 1.  MRI scanning conditions
A : 2008–2011 breast MRI scanning conditions
Scanning 
method
Image 
section Sequence
TR
（ms）
TE
（ms）
FA
（°）
FOV
（mm） Matrix
Slice 
thickness
（mm）
Slice  
addition Number
Scan 
duration
T2WI
（Bilateral） Sagittal 2D-FSE 3,500 102 90 180 256×224 3 30 2 2'13"
Dynamic 
FS T1WI（Bilateral）
0 s, 1 min, 2 min, 
8 min
Sagittal VIBRANT 4.5 2.1 12 200 256×206 2.4 128 1 1'30"
B :  2012 breast MRI scanning conditions
Scanning 
conditions
Image 
section Sequence
TR
（ms）
TE
（ms）
FA
（°）
FOV
（mm） Matrix
Slice 
thickness
（mm）
Slice  
addition Number
Scan 
duration
T2WI
（bilateral） Axial FRFSE-XL 3,800 102 90 350 448×256 2 90 2 4’57"
FS T2WI 
（bilateral） Axial FRFSE-XL 4,400 102 90 350 448×256 2 90 2 5’31"
Dynamic 
FS T1WI （bilateral）
0 s, 45 s, 2 min 15 s, 
8 min
Axial VIBRANT 6.1 2.98 10 350 384×256 1.6 248 - 1’33"
Table 2.  MRI and MMG ndings
DCIS NE-DCIS
n＝ 71 n＝ 8 P
MRI ndings
Lesion type
Mass 12（16.9％） 5（62.5％）
Non-mass 54（76.1％） 2（25.0％） 0.007
Focus 5（ 7.0％） 1（12.5％）
TIC pattern on DCE-MRI
Washout 27（38.0％） 7（87.5％）
Plateau 20（28.2％） 1（12.5％） 0.023
Persistent 24（33.8％） 0（ 0.0％）
Duct ectasia
（＋） 18（25.0％） 4（50.0％） 0.21
（-） 53（75.0％） 4（50.0％）
MMG
Calcication
（＋） 43（60.1％） 0（ 0.0％） 0.002
（-） 28（39.1％） 8（100％）
DCE-MRI : dynamic contrast-enhanced MRI, MMG : mammography,
MRI : magnetic resonance imaging, TIC : time–signal intensity curve
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Fig. 3.  Neuroendocrine ductal carcinoma in situ （NE-DCIS） case
Female, 40 years of age, mass-type
Dynamic FS T1WI axial image : a）contrasting at 1 min, b）contrasting at 8 min, c）time-signal intensity curve （TIC）. 
In a-c, the left breast shows contrast enhancement of a mass-type lesion （a : arrow）.  On dynamic contrast-enhanced 
（DCE）-MRI, TIC shows a washout pattern.
Female, 74 years of age, non-mass-type
Dynamic FS T1WI axial image : d）1 min, e）8 min, f）time-signal intensity curve（TIC）. In d–f, the right breast shows 
contrast enhancement of a non-mass-type lesion（d : arrows）, and on dynamic contrast-enhanced （DCE）-MRI, TIC 
shows a plateau pattern, as the only case of this type in this study.
Case showing bloody duct ectasia
Dynamic FS T1WI axial image : g）pre-contrast, h）1 min. A mass-type lesion（h : arrows）and bloody duct ectasia （g : arrow-
heads）delineated with high-signal intensity on dynamic contrast-enhanced（DCE）-MRI pre-contrast T1-weighted imaging.
Female, 40 years of age, mass-type
Female, 74 years of age, non-mass-type
Female, 39 years of age, Case showing bloody duct ectasia
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the plateau pattern on DCE-MRI, and the only case of this type in this study.  Bloody duct 
ectasia delineation with high-signal intensity on pre-contrast T1-weighted imaging was observed in 
4（50％）patients with NE-DCIS and in 18（25％）with non-NE-DCIS ; however, no signicant 
difference was observed between the groups.  Figure 3g and h presents a case with mass-type 
lesion and bloody mammary duct ectasia.  Calcication using MMG was detected in none of the 
patients with NE-DCIS, but in 43（60.1％）with non-NE-DCIS, revealing a signicant intergroup 
difference（P＝ 0.002）.
Discussion
　It was revealed that NE-DCIS showed that the type of lesion is signicantly more frequently 
the mass type and that TIC in DCE-MRI shows more washout pattern than non NE-DCIS.
　The incidence of NE-DCIS in the present study of 10.1％ was marginally higher than previ-
ously reported at 6.8％ of all DCIS cases1）, as was the mean age of patients with NE-DCIS（57.3 
years）compared to 50.4 years1）.  In addition, a palpable mass is rarely encountered with DCIS, 
and the primary complaint of many patients is bloody discharge from the nipple1-4）.  We did 
not examine the presence or absence of these symptoms in our patients ; however, the rate of 
bloody duct ectasia delineation on MRI was 50％ for patients with NE-DCIS and 25％ for those 
with non-NE-DCIS（not signicant）, and delineation was found to be more common in NE-
DCIS than in non-NE-DCIS.  In one study, the imaging ndings for NE-DCIS were character-
ized by dilated mammary ducts and segmental contrast enhancement on MRI 5）.
　According to consensus MRI ndings for DCIS, the most common lesion is a non-mass-type
（59％ of patients）, followed by mass-type（14％）, and focus-type（12％）7）.  In our study, non-
mass-type lesions were most common in patients with non-NE-DCIS（76.1％）, and mass-type 
lesions accounted for only 16.9％.  In patients with NE-DCIS, mass-type lesions were most com-
mon at 87.5％, with a signicant difference observed between patients with NE-DCSI and those 
with non-NE-DCIS.  Furthermore, intense segmental contrast enhancement was observed in 1 of 
9（11％）NE-DCIS lesions and in 33 of 71（46.5％）non-NE-DCIS lesions in the present study, 
indicating signicantly lower contrast enhancement in NE-DCIS compared with non-NE-DCIS ;  
these results differed from the NE-DCIS ndings reported by Kawasaki et al 5）.
　On DCE-MRI, TIC was previously reported to show a plateau pattern more frequently than a 
washout pattern for DCIS 8）; however, we observed the washout pattern in 38.0％ of our patients 
with non-NE-DCIS, a persistent pattern in 33.8％, and plateau pattern in 28.2％, with no signi-
cant intergroup differences in the contrast pattern.  On the other hand, for patients with NE-
DCIS, the washout pattern was observed in the majority（87.5％）of patients, with a signicant 
intergroup difference.
　Calcification on MMG is reportedly rare in patients with NE-DCIS1, 7, 9）, and our cohort 
showed the same trend, with no calcication observed in any patient with NE-DCIS by MMG. 
In contrast, calcication was observed in 43（60.1％）patients with non-NE-DCIS, thus there was 
a significant difference in the rendering rate of calcification between NE-DCIS and non-NE-
DCIS cases.  Although we did not analyze the ultrasound ndings, hypoechoic lesions with a 
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relatively distinct border are often found in NE-DCIS, with images characteristic of duct ectasia 
and lesions showing abundant blood ow on color Doppler imaging 1, 5, 7, 9）.  In this study, mass-
type lesions and TIC washout pattern were signicantly more common in patients with NE-DCIS 
than in those with non-NE-DCIS on MRI and DCE-MRI, respectively.  In addition, although no 
signicant differences were observed in the rate of bloody mammary duct ectasia, it was more 
common in patients with NE-DCIS than in those with non-NE-DCIS.  Finally, calcication was 
observed on MMG in 60.1％ of non-NE-DCIS cases, with none found in NE-DCIS cases, thus 
indicating a signicant between-group difference.
　NE-DCIS is a relatively rare disease and a new disease concept, and thus the recommenda-
tions for therapy, prognosis, and pathology have not yet been sufciently elucidated.  Neverthe-
less, we believe it will become more clinically signicant to differentiate between NE-DCIS and 
non-NE-DCIS, and that more cases must be accumulated in the future to establish guidelines for 
the prognosis and treatment of pateints with NE-DCIS.
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